Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: Dosing patterns and effectiveness in daily clinical practice

Clinical and Experimental Rheumatology

Volumn 31, Issue 4, 2013, Pages 559-565

  Ramirez Herraiz E ^a   Escudero Vilaplana, V ^b,c   Alanon Plaza E ^a   Trovato Lopez N ^b,c   Herranz Alonso, A ^b,c   Morell Baladron A ^a   Sanjurjo Saez M ^b,c  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Adalimumab; Efficiency; Etanercept; Infliximab; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SPAIN; TREATMENT DURATION;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84883543454     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. ALAMANOS Y, VOULGARI PV, DROSOS AA: Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: A systematic review. Semin Arthritis Rheum 2006; 36: 182-8.
2. GABRIEL SE, MICHAUD K: Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 2009; 11: 229.
3. CARMONA L, VILLAVERDE V, HERNANDEZGARCIA C, BALLINA J, GABRIEL R, LAFFON A: The prevalence of rheumatoid arthritis in the general population of Spain. Rheumatology (Oxford) 2002; 41: 88-95.
4. CARBONELL J, COBO T, BALSA A, DESCALZO MA, CARMONA L: The incidence of rheumatoid arthritis in spain: Results from a nationwide primary care registry. Rheumatology (Oxford) 2008; 47: 1088-92.
5. CHEN YF, JOBANPUTRA P, BARTON et al.: A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their costeffectiveness. Health Technol Assess 2006; 10:iii-iv, xi-xiii, 1-229.
6. AGARWAL SK: Biologic agents in rheumatoid arthritis: An update for managed care professionals. J Manag Care Pharm 2011; 17: S14-8.
7. EMI AIKAWA N, de CARVALHO JF, ARTUR ALMEIDA SILVA C, BONFA E: Immunogenicity of anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 2010; 38: 82-9.
8. DORE RK, MATHEWS S, SCHECHTMAN J et al.: The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007; 25: 40-6.
9. BARTELDS GM, WIJBRANDTS CA, NURMOHAMED MT et al.: Clinical response to adalimumab: Relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 921-6.
10. BARTELDS GM, KRIECKAERT CL, NURMOHAMED MT et al.: Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011; 305: 1460-8.
11. PASCUAL-SALCEDO D, PLASENCIA C, RAMIRO S et al.: Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) 2011; 50: 1445-52.
12. RUIZ-MONTESINOS MD, HERNANDEZ-CRUZ B, ARIZA-ARIZA R, CARMONA L, BALLINA J, NAVARRO-SARABIA F: [cost analysis in a cohort of rheumatoid arthritis patients managed in rheumatology units in Spain]. Reumatol Clin 2005; 1: 193-9.
13. RUBIO-TERRES C, ORDOVAS BAINES JP, PLA POBLADOR R et al.: [use and cost of biological disease-modifying anti-rheumatic drugs in Spain (Praxis study)]. Farm Hosp 2007; 31: 78-92.
14. MALHAN S, PAY S, ATAMAN S et al.: The cost of care of rheumatoid arthritis and ankylosing spondylitis patients in tertiary care rheumatology units in Turkey. Clin Exp Rheumatol 2012; 30: 202-7.
15. OLLENDORF DA, KLINGMAN D, HAZARD E, RAY S: Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin Ther 2009; 31: 825-35.
16. SCHABERT VF, WATSON C, GANDRA SR, GOODMAN S, FOX KM, HARRISON DJ: Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the united states. J Med Econ 2012; 15: 264-75.
17. GILBERT TD, Jr., SMITH D, OLLENDORF DA: Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: A retrospective cohort study. BMC Musculoskelet Disord 2004; 5: 36.
18. FITZCHARLES MA, CLAYTON D, MENARD HA: The use of infliximab in academic rheumatology practice: An audit of early clinical experience. J Rheumatol 2002; 29: 2525-30.
19. STERN R, WOLFE F: Infliximab dose and clinical status: Results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol 2004; 31: 1538-45.
20. AGARWAL SK, MAIER AL, CHIBNIK LB et al.: Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis Rheum 2005; 53: 872-8.
21. ETEMAD L, YU EB, WANKE LA: Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis. Manag Care Interface 2005; 18: 21-7.
22. OLLENDORF DA, MASSAROTTI E, BIRBARA C, BURGESS SM: Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. J Manag Care Pharm 2005; 11: 383-93.
23. WU E, CHEN L, BIRNBAUM H, YANG E, CIFALDI M: Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. Curr Med Res Opin 2008; 24: 2229-40.
24. BREEDVELD FC, WEISMAN MH, KAVANAUGH AF et al.: The premier study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26-37.
25. ARIZA-ARIZA R, NAVARRO-SARABIA F, HERNANDEZ-CRUZ B, RODRIGUEZ-ARBOLEYA L, NAVARRO-COMPAN V, TOYOS J: Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review. Rheumatology (Oxford) 2007; 46: 529-32.
26. OGALE S, HITRAYA E, HENK HJ: Patterns of biologic agent utilization among patients with rheumatoid arthritis: A retrospective cohort study. BMC Musculoskelet Disord 2011; 12: 204.
27. St CLAIR EW, WAGNER CL, FASANMADE AA et al.: The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from attract, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1451-9.
28. van VOLLENHOVEN RF, BRANNEMARK S, KLARESKOG L: Dose escalation of infliximab in clinical practice: Improvements seen may be explained by a regression-like effect. Ann Rheum Dis 2004; 63: 426-30.
29. SCHABERT VF, BRUCE B, FERRUFINO CF et al.: Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: A US-based retrospective comparative effectiveness study. Curr Med Res Opin 2012; 28: 569-80.
30. HARRISON DJ, HUANG X, GLOBE D: Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis. Am J Health Syst Pharm 2010; 67: 1281-7.
31. HUANG X, GU NY, FOX KM, HARRISON DJ, GLOBE D: Comparison of methods for measuring dose escalation of the subcutaneous tnf antagonists for rheumatoid arthritis patients treated in routine clinical practice. Curr Med Res Opin 2010; 26: 1637-45.
32. MOOTS RJ, HARAOUI B, MATUCCI-CERINIC M et al.: Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: Evidence from clinical practice. Clin Exp Rheumatol 2011; 29: 26-34.
33. WAILOO AJ, BANSBACK N, BRENNAN A, MICHAUD K, NIXON RM, WOLFE F: Biologic drugs for rheumatoid arthritis in the medicare program: A cost-effectiveness analysis. Arthritis Rheum 2008; 58: 939-46.